Proactive Investors - Run By Investors For Investors

Achieve Life Sciences shares slump on its public stock offering

Achieve Life Sciences is a pharma group that specializes in smoking cessation products
The public stock offering is set to raise US$12m

Shares in Achieve Life Sciences Inc (NASDAQ:ACHV), a clinical-stage pharmaceutical group specializing in smoking cessation, have plummeted on its announcement of another public stock issue.

In early trade, Achieve Life Sciences slumped 30.4% to US$3.62 on the news.

The offering, which is set to raise US$12m,  is comprised of class A shares priced at US$4 per share; each unit consists of one share plus a five-year warrant to purchase one share of common stock with an exercise price of $4 per share.

The outreach effort also includes class B units, priced at a public offering price of US$1,000 per unit, with each unit comprised of one share of Series A preferred stock, which is convertible into 250 shares of common stock that also carries an exercise price of $4 per share.

A total of 710,500 shares of common stock; 9,158 shares of Series A preferred stock convertible into 2,289,500 shares of common stock; and total warrants to purchase 3,000,000 shares of common stock will be issued as part of the offering.

Ladenburg Thalmann & Co is the book runner on the offering.

View full ACHV profile View Profile

Achieve Life Sciences Inc Timeline

Related Articles

November 20 2018
Borko Moric will succeed Parilla as chief executive officer. Bojan Moric will become the company's chief operations officer
January 04 2019
In its outlook for 2019, the firm said the focus was now “not only on continuous improvements in feed grade and recoveries but on expanding the business into new jurisdictions”
Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use